Massachusetts General Hospital
Corporate & Foundation Relations
Office of Development

PRIVATE FUNDING OPPORTUNITIES: MAY 19, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

*Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.*

1. Research Grant Program: A-T Post Doctoral Fellowship Award, A-T Children's Project

Ataxia-telangiectasia, or A-T, is a rare genetic disease that attacks children, causing progressive loss of muscle control, immune system problems, and a high rate of cancer. A-T affects a large variety of systems in the body, causing symptoms that affect health and daily living.

The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of A-T. The A-T Children's Project is determined to find a timely cure, or life-improving treatments, for this serious disease. Postdoctoral fellowships are available. The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T.

The A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on:

- translational (bench to bedside) research
- clinical studies

As such, these types of applications will be given priority funding.

Applicants should also be aware that meritorious proposals may be rejected if:

- The proposed research is too far from being relevant to a therapeutic intervention
- The sponsor's Scientific Advisory Board finds the research redundant and in no need of validation
- The proposed research is likely to happen anyway, without the sponsor's support
- The research cannot realistically be achieved with the proposed budget

Award Amount: $60,000-$80,000 paid over 2 years
Indirect Costs: None
LOI Deadline: Aug 1, 2017
Website: http://www.communityatcp.org/FellowshipAward

2. Research Grant Program: Investigator Initiated Grants, A-T Children's Project
The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of A-T. The A-T Children's Project is determined to find a timely cure, or life-improving treatments, for this serious disease. The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T.

Applicants please note that unless specific Requests for Applications are present, the A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on: pre-clinical research and clinical studies.

As such, these types of applications will be given priority funding.

Applicants should also be aware that meritorious proposals may be rejected if:

- The proposed research is too far from being relevant to a therapeutic intervention
- The sponsor's Scientific Advisory Board finds the research redundant and in no need of validation
- The proposed research is likely to happen anyway, without the sponsor's support
- The research cannot realistically be achieved with the proposed budget

Award Amount: $150,000 paid over 1-2 years
Indirect Costs: None
LOI Deadline: Aug 1, 2017
Website: https://atcp.org/grantguidelines

3. Eliminating Barriers to Innovative Cardiovascular Therapies to Improve Patient Care and Outcomes, Bristol-Myers Squibb (BMS)
Pfizer and Bristol-Myers Squibb (BMS) are working together on grants in support of innovative cardiovascular therapies. The goal of these grants is to improve patient care and outcomes through therapy innovation.

Proposals are requested dealing with the RFP Topic: Eliminating barriers to innovative cardiovascular therapies to improve patient care and outcomes.

The intended audience is: Patients, health care providers, payers, hospitals, pharmacy/pharmacists, administrative agencies and advocates.

The geographic region is: U.S. only.

RFP Rationale: Chronic disease is the leading cause of death and disability in the United States. Accessing affordable treatments is vital for all Americans. There are many factors that may limit both patient and provider ability to access the newest and most innovative therapies including restrictive formularies, step therapy, non-medical switching, cost and cumbersome administrative processes including prior authorization and tier exception processes. The strategies employed to address these barriers may include:

- Gaining an understanding of barriers from each stakeholder's point of view (HCP, Patient, administrative staff, caregivers, others);
- Developing best practices that can inform advocacy organizations and medical societies, including the role each could play in the evolving access landscape.

Award Amount: $125,000 for 1 year
Indirect Costs: Unpublished
LOI Deadline: Jun 28, 2017
Website: https://www.bms.com/about-us/responsibility/corporate-giving/current-funding-opportunities/request-for-proposals-education.html

4. Request for Education (RFE): Immunotherapy mechanism of action and treatment response in head & neck cancer / Immune checkpoint inhibitors / Immune-related adverse events (irAEs) and management, Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb has released an Independent Medical Education Request for Educational Support (RFE) in the following Therapeutic Areas:

- Immunotherapy agents in oncology
- Squamous Cell Carcinoma of the Head & Neck (SCCHN)

Areas of Interest are:

- Immunotherapy mechanism of action and treatment response in head & neck cancer
- Immune checkpoint inhibitors
- Immune-related adverse events (irAEs) and management

Educational Design: Comprehensive, engaging, and innovative education initiative that includes:

- Live Satellite Symposium at the 2017 American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting (9/24/2017- 9/27/2017)
- Live video simulcast of the symposium
- Web-based enduring activity leveraging the medical content from the live meeting

Knowledge, performance and competency based outcome measures according to Mooreâ€TMs Level 5 are required using objective measures.

Intended Audience, may include, but is not limited to:

- Medical Oncologists, Radiation Oncologists, Surgical Oncologists, H&N Surgeons
- Multidisciplinary Oncology Team: NPs/PAs, PharmDs, Pharmacists, Nurses, etc

Accreditation: ACCME, ANCC, ACPE, CEU, and others as appropriate

Geographic Coverage: United States

Background:
There is a large amount of clinical data available in immunotherapy for the treatment of advanced head & neck cancer. Understanding how the immune system relates to cancer, expected responses to therapy, and the recognition and management of immune-related adverse events (irAEs) have become areas of focus for the oncology community. Therefore, an integration of the data in a live setting for a broad audience at a key professional meeting is warranted. Since many oncologists and healthcare professionals working in a multidisciplinary oncology team do not have the opportunity to attend live meetings, it is necessary and important to make the activities correlated with these meetings available through internet/computer-based modalities as well.

Educational needs and professional practice gaps:

BMS is seeking proposals to close the following independently identified educational gaps for oncology HCPs that treat advanced head & neck cancer.

- Comprehensive knowledge: Understand the latest science and clinical trial data on the use of immunotherapy agents in head & neck cancer including the role of the immune system in cancer and the MOA of immunomodulatory agents
- Treatment algorithms for irAEs: Increasing the awareness and understanding of the treatment of irAEs and implementing best practices into routine clinical practice.
- Implementation of cancer immunotherapy treatment: Apply practice guideline recommendations in the use of immunotherapy in the treatment of head & neck cancer; Describe the potential impact of HPV, PD-L1 status, and expression profiling (ie, IFNÎ³) on a patientâ€TMs clinical response to immune checkpoint inhibitors
- Improving patient outcomes: Identify appropriate candidates for approved and emerging cancer immunotherapies for recurrent or metastatic head & neck cancer; Outline methods to incorporate multidisciplinary discussions with the care team in the differential diagnosis of head & neck cancer

Specific Area of Interest
BMS is interested in funding an innovative, interactive, educational activity that addresses the above educational needs.

The content and/or the format of the CME/CE activity and its related materials must be designed in such a way that it addresses the educational needs of health care professionals and,

if appropriate, tools/aids that can help health care practitioners communicate with or better manage their patients.

Presentations and content must give a scientifically sound, fair and balanced overview of new and emerging therapeutic options currently available or in development to manage or prevent this disease.

Award Amount: $200,000
Indirect Costs: Unpublished
Submission Deadline: Jun 2, 2017
Website: https://www.bms.com/about-us/responsibility/corporate-giving/current-funding-opportunities/request-for-proposals-education.html

5. Gilead Sciences Research Scholars Program in Liver Disease - The Americas, Gilead Sciences, Inc./Gilead Sciences Pty Ltd
The mission of the Program is to support innovative scientific research that will advance knowledge in the field of liver disease and provide support for research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of liver disease.

The program is designed to support basic and clinical research in the field of liver disease. Areas of research may include, but are not limited to:

- Chronic viral hepatitis
- End-stage liver disease and its complications
- Non-viral chronic liver diseases
- Basic, clinical, and translational research related to liver disease
- Health economics outcomes research relating to liver disease

Award Amount: $130,000 paid over 2 years
Indirect Costs: 10%
Application Deadline: Jul 14, 2017
Website: http://researchscholarsld-us.gilead.com

6. Gilead Sciences Research Scholars Program in Cystic Fibrosis, Gilead Sciences, Inc./Gilead Sciences Pty Ltd
The Program is designed to support basic, translational, and clinical research in the field of cystic fibrosis. Areas of research may include, but are not limited to:

- CF basic pathophysiology
- CF-specific microbiology
- CF-related epidemiology, clinical care, and health-related outcomes

Award Amount: $130,000 paid over 2 years
Indirect Costs: 8%
Application Deadline: Jul 21, 2017
Website: http://researchscholars.gilead.com/en/cystic_fibrosis_portal/application-information/research-proposal-guidelines

7. FOP Competitive Research Grant Program, International Fibrodysplasia Ossificans Progressiva Association (IFOPA)
The IFOPA offers the FOP Competitive Grant Program to help accelerate development of a safe and transformative therapies for the disease. The program provides, through a competitive application process, research funding to scientists conducting research on fibrodysplasia ossificans progressiva (FOP).

Research grants should focus on discovery and advancement of new therapeutic approaches to FOP with preference towards approaches likely to have near-term clinical or translational relevance.

Award Amount: $100,000 for 1 year
Indirect Costs: None
Proposal Deadline: Jun 30, 2017
Website: http://www.ifopa.org/funding_opportunities

8. Advanced Postdoctoral Fellowships, JDRF
The program is designed to attract qualified and promising health scientists, to provide an opportunity to receive full time research training, and to assist these promising individuals in transitioning from a fellowship to an independent (faculty-level) position. JDRF envisions the 3-year award term as a period in which fellows will receive critical research training that will position them to work at the leading edge of their chosen field. An additional, optional 1-year transition award will further assist fellows to proceed to independent faculty or research appointments and will serve as a bridge between the fellowship and independent competitive research funding. During the fellowship phase, the applicant is required to work with a sponsor who can provide a training environment conducive to beginning a career in diabetes-relevant research.

Fellowships will be awarded on the basis of the applicant's previous experience, academic record, the caliber of the proposed research, the quality of the mentor, training program, and environment, and the applicant's potential to obtain an independent research position in the future. The relevance of the proposal to the cause, cure, treatment, and/or prevention of diabetes and its complications will also be considered. Applicants are encouraged to submit projects aligned with JDRF Research Priority Areas. While not a requirement, a proposal that is aligned with JDRF Priority areas will be given priority consideration in the review process.

The applicant's professional ability and promise for a research career in type 1 diabetes will hold the highest priority in selection and will be assessed on the basis of the letters of recommendation, career plans, prior clinical and research training, academic transcripts, and the mentor's endorsement. Location in a department that will provide a stimulating research environment is an additional factor that will be considered in evaluating applicants.

Fellowship research may be conducted at foreign and domestic, for-profit and nonprofit, and public and private organizations, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.

Award Amount: $270,000 paid over 3 years
Indirect Costs: None
Application Deadline: Jun 28, 2017
Website: http://grantcenter.jdrf.org/rfa/advanced-postdoctoral-fellowships/

9. Career Development Awards, JDRF
JDRF fosters the development and productivity of the best and the brightest established independent researchers who will bridge the gap between the bench and bedside. The primary purpose of the Career Development Award is to attract qualified and promising scientists early in their faculty careers and to give them the opportunity to establish themselves in areas that reflect the JDRF research emphasis areas.

In the five-year term of the award, awardees will focus their research efforts on a subject directly related to JDRF mission goals and research priorities, and position themselves to work at the leading edge of type 1 diabetes research. These awards are designed to assist exceptionally promising investigators. Although JDRF is especially interested in fostering careers in clinical investigation, Career Development Awards may emphasize either basic or clinical topics.

Career Development Award research may be conducted at foreign and domestic, for-profit and nonprofit, and public and private organizations - such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.

Award Amount: $750,000 paid over 5 years
Indirect Costs: 10%
Application Deadline: Jun 28, 2017
Website: http://grantcenter.jdrf.org/rfa/

10. Postdoctoral Fellowships, JDRF
Postdoctoral fellowships are designed to attract qualified, promising scientists entering their professional career in the T1D research field. The applicant is required to work with a sponsor who can provide a training environment conducive to beginning a career in type 1 diabetes-relevant research.

Fellowship research may be conducted at foreign and domestic, for-profit and nonprofit, and public and private organizations such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.

Fellowships will be awarded on the basis of the applicant's previous experience, academic record, the caliber of the proposed research, and the quality of the mentor, training program, and environment. The relevance of the proposal to the cause, cure, treatment, and/or prevention of diabetes and its complications will also be considered. Applicants are encouraged to submit projects aligned with JDRF Research Priority Areas. While not a requirement, a proposal that is aligned with JDRF Priority areas will be given priority consideration in the review process.

The applicant's professional ability and promise for a research career in type 1 diabetes will hold the highest priority in selection and will be assessed on the basis of the letters of recommendation, career plans, prior clinical and research training, academic transcripts, and the mentor's endorsement. Location in a department that will provide a stimulating research environment is an additional factor that will be considered in evaluating applicants.

Award Amount: Up to $189,012 paid over 3 years
Indirect Costs: None
Application Deadline: Jun 28, 2017
Website: http://grantcenter.jdrf.org/information-for-applicants/grant-mechanism-descriptions/

11. Early Career Patient-Oriented Diabetes Research Awards, JDRF
The award is designed to provide crucial support to investigators who plan to pursue a career in type 1 diabetes-related clinical investigation. Awards are made in the later stages of training and include the ability for recipients to transition to independent faculty or research appointments.

Awards will be made to applicants who have demonstrated superior scholarship and show the promise for future achievement in clinical research, particularly in those areas that require the unique training of a clinical investigator. Applicants are encouraged to submit projects aligned with JDRF Research Priority Areas. While not a requirement, a proposal that is aligned with JDRF Priority areas will be given priority consideration in the review process.

Research may be conducted at foreign and domestic, for-profit and nonprofit, and public and private organizations-such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.

Award Amount: Up to $750,000 for up to 4 years
Indirect Costs: 10%
Application Deadline: Jun 28, 2017
Website: http://grantcenter.jdrf.org/rfa/

12. KDA Research Grants, Kennedy's Disease Association (KDA)
Because the KDA is relatively small and funding is limited, our focus in recent years has been to provide "seed-money" to post-doc and other young researchers who do not currently have the funding or credentials to receive funding from larger organizations such as the National Institute of Health or the MDA. This "seed-money" normally provides the researcher an opportunity to further his/her research while giving him/her time to apply for other grants.

Award Amount: $50,000
Indirect Costs: 5%
Proposal Deadline: Jul 7, 2017
Website: https://www.kennedysdisease.org/index.php/kennedy-s-disease-research

13. Novel Research Grant Program - New Research Grants for Novel Approaches to Lupus, Lupus Research Alliance
The Lupus Research Institute (LRI) invites applications for financial support for idea-driven, novel research projects relevant to basic, translational or clinical investigation in lupus.

Novel Research Grants provide early stage support for exceptionally creative and innovative approaches to major challenges in lupus research. Successful proposals will advance novel hypotheses and/or technologies that have the potential to stimulate new research directions and propel the field forward. Applications will be judged principally on novelty of the hypotheses, scientific quality, strength of approach, relevance to lupus, likelihood of success, and potential impact for those living with lupus. Rationale for the hypotheses proposed rather than amount of preliminary data will be emphasized. Continuations of long-term research projects are not appropriate for this submission.

The program goals are to stimulate investigation of underexplored pathways and generate transformative discoveries in lupus that can drive the development of safer and more effective treatments. Investigations into the fundamental mechanisms of lupus and its complications, explorations of novel targets and pathways, and applications involving novel technologies and interdisciplinary approaches are particularly encouraged.

The Lupus Research Institute particularly encourages projects based on novel explorations of human lupus biology - innovative studies that use human material to address the physiological, cellular, molecular and/or genetic basis of human lupus.

Award Amount: $300,000 paid over 3 years
Indirect Costs: None
Application Deadline: Jul 10, 2017
Website: http://www.lupusresearch.org/lupus-research/for-researchers.html

14. Research Grants, Migraine Research Foundation (MRF)
The Migraine Research Foundation (MRF) and the Association of Migraine Disorders (AMD) have announced a joint Request for Proposals for migraine research grants. MRF is committed to discovering the causes, improving the treatments, and finding a cure, and AMD stimulates increased research specifically in the area of migraine disorders. The sponsors are looking for projects that will help sufferers by advancing our ability to understand and treat migraine. As a result, the sponsors seek to provide seed-money grants for projects that are important, achievable, and innovative that will ultimately lead to better treatment and quality of life for sufferers of migraine and migraine disorders.

While the sponsors welcome all proposals relevant to basic or clinical migraine research, they are particularly interested in translational projects and those related to migraine variants, childhood migraine, and chronic migraine.

Award Amount: $50,000 for 1 year
Indirect Costs: None
Proposal Deadline: Jul 28, 2017
Website: http://www.migraineresearchfoundation.org/for-migraine-researchers.html

15. Young Investigator (YI) Award and Young Investigator (YI-SCA) Award for SCA Research, National Ataxia Foundation (NAF)
This award was created to encourage young clinical and scientific investigators to pursue a career in the field of ataxia research. It is NAF's hope that ataxia research will be invigorated by the work of young, talented individuals supported by this award.

Due to the larger availability of funding for Ataxia-Telangiectasia (A-T), those research proposals will receive a lower priority. However, a higher ranking will be given to those Ataxia-Telangiectasia research studies that lend themselves to an overall better understanding of the ataxia process.

The YI-SCA Award is available specifically for the study of the spinocerebellar ataxias.

Award Amount: $35,000-$50,000 for 1 year
Indirect Costs: None
Pre-Application Deadline: Aug 1, 2017
Website: http://ataxia.org/

16. Investigator-Initiated Research Grants, National Institute for Health Care Management (NIHCM)/National Institute for Health Care Management Research and Educational Foundation (NIHCM Foundation)
The purpose of the grants is to support innovative research that will advance the existing knowledge base in the areas of health care financing, delivery, management and/or policy. Studies must have strong potential to yield insights that can be used to have a positive impact on the U.S. health care system by reducing spending, improving quality of care, and/or expanding access to insurance coverage and health care services.

Award Amount: $50,000-$60,000
Indirect Costs: 12%
LOI Deadline: Jul 10, 2017
Website: http://www.nihcm.org/grants/research-grants

17. Research Seed Money Grant for Malonic Aciduria, National Organization for Rare Disorders, Inc. (NORD) New
The purpose of the NORD Research Grant Program is to encourage meritorious scientific and clinical studies designed to improve the diagnosis or therapy of rare "orphan" diseases. Grants will be awarded to academic researchers to initiate small scientific research studies or clinical trials, the results of which could be used to obtain funding from NIH, FDA or other funding agencies, or to attract a corporate sponsor. Procedures or proposed therapeutic trials may be new, based on recent biochemical or pharmacological evidence, or in preliminary stages of clinical investigation. Evaluation of proposals will include careful consideration of protocol design, objectiveness of parameters measured, and statistical evaluation proposed. Protocols that will focus on cause, early detection, diagnosis, or treatment (pharmacological, devices, surgery, or dietary) will be given priority.

NORD, with funding from The Hope Fund, is accepting applications for scientific and/or clinical research studies related to malonyl-CoA decarboxylase deficiency, a rare metabolic condition that prevents the body from converting certain fats to energy. The signs and symptoms of this disorder are variable, but may include delayed development in childhood, hypotonia, seizures, diarrhea, vomiting, metabolic acidosis, hypoglycemia, ketosis, abnormal urinary compounds, lactic academia and hypertrophic cardiomyopathy. This condition is caused by mutations in the malonyl-CoA decarboxylase gene (MLYCD) gene, and is inherited as an autosomal recessive trait. The MCD enzyme is involved in the degradation of malonyl-CoA and it appears that inhibition of fatty acid synthesis as a result of malonyl-CoA

accumulation is responsible for at least some of the clinical manifestations of the disorder. This condition is known as malonic aciduria, malonic acidemia, malonyl-coenzyme A decarboxylase deficiency, and MCD deficiency.

Award Amount: $50,000
Indirect Costs: None
Application Deadline: Jun 23, 2017
Website: https://rarediseases.org/for-clinicians-and-researchers/research-opportunities/requests-proposals/

18. Global Research Awards for Nicotine Dependence (GRAND), Pfizer, Inc.
The overall mission of the GRAND program is to advance the pharmacological treatment of tobacco and nicotine dependence.

Research projects should aim to provide information that could directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Examples could include:

- Observational or interventional studies of pharmacotherapy
- Optimization of the use of currently available medication
- Effectiveness of treatment in real-life settings
- Development or use of new medications for cessation or harm reduction
- Specifically designed interventions in subtypes of tobacco/nicotine users
- Use of existing databases to inform the clinical use of pharmacotherapy
- Policy interventions to increase use of pharmacotherapy.

Non-human studies and educational programs fall outside of the scope of the GRAND program for 2017 and will not be considered for an award.

Examples of other topics that fall outside of the scope of the GRAND program for 2017 and will not be considered for an Award, unless directly related to advancing the use of pharmacotherapy, include:

- Genetics
- Epidemiology of tobacco use
- Tobacco control policy not focused on pharmacotherapy

Award Amount: $50,000-$200,000
Indirect Costs: None
Application Deadline: Jul 3, 2017
Website: http://www.grandawardsprogram.org/

19. Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Understanding Oncology Clinical Trial Outcomes and Comparative Assessment, Pfizer, Inc. New

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

Geographic Scope: United States only

Clinical Area: Oncology Outcomes & Evidence

Specific Area of Interest for this CGA:
It is our intent to support continuing professional development programs (CME/CE) for managed care decision-makers, formulary decision-makers, other payor decision-makers, pharmacists/pharmacy directors, and medical oncologists/medical directors. Proposed programs should focus on increasing the understanding of one or more of the following topics, in order of priority:

1. Formulary Class Review & Considerations: Examining Current and Emerging Agents in the CDK 4/6 Inhibitor Class for the Treatment of HER2(-)/ER(+) Advanced or Metastatic Breast Cancer
2. The use of Patient Reported Outcomes (PROs) in Oncology Versus Other Therapeutic Areas and a Primer for Payers to the PRO-Common Terminology Criteria for Adverse Events Tool (PRO-CTCAE tool)
3. Application & Limitations of Evidenced-Based Methods for Indirect Treatment & Trials Comparisons: Value frameworks (ASCO Value Framework, NCCN Evidence Blocks, etc) and Real World Data for indirect treatment comparisons; and Network Meta-Analysis (NMA), Simulated Treatment Comparison (STC), Match Adjusted Treatment Comparison (MAIC), etc. for indirect trials comparisons
4. Challenges with Oncology Trial Design/Approvals & Endpoints in Value Assessment. For example:
    - Overall Survival (OS) vs. Progression Free Survival (PFS)
    - Earlier FDA approvals based upon Phase 2 data
    - The Quality Adjusted Life-Years (QALY) dilemma
    - Forthcoming novel primary endpoints or endpoints analyses (invasive disease free survival (iDFS), restricted-mean survival times (RMST), intermediate survival endpoints, durable response, etc.)

All activity types will be considered through this CGA including live events, on-agenda sessions, satellite symposia, workshops, online courses, print materials, other enduring materials. Of particular interest are activities taking place at the Academy of Managed Care Pharmacy (AMCP) Nexus in October 2017 and/or the AMCP Annual Meeting in April 2018; and/or Fall or Spring Managed Care Forums of the American Association of Integrated Healthcare Delivery Systems (AAIHDS), the American Association of Managed Care Nurses (AAMCN), and the National Association of Managed Care Physicians (NAMCP).

Efforts should be made to encourage interaction, incorporate patient case discussions, and provide opportunities to extend and reinforce learning opportunities beyond the live setting.

Award Amount: Up to $200,000 paid over 2 years
Indirect Costs: 28%
Application Deadline: Jun 21, 2017
Website: http://www.pfizer.com/purpose/medical-grants/process

20. Independent Grants for Learning & Change: Request for Proposals (RFP) - Shared Management of Psoriatic Arthritis, Pfizer, Inc.
The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

The intent of this document is to encourage organizations with a focus in healthcare professional education and/or quality improvement to submit a letter of intent (LOI) in response to a Request for Proposal (RFP) that is related to education in a specific disease state, therapeutic area, or broader area of educational need.

Specific Area of Interest for this RFP: Evidence indicates that many patients with Psoriatic Arthritis (PsA) remain undiagnosed, and those who have been diagnosed are not receiving optimal care. It is our intent to support projects that focus on the coordinated management and identification of patients with psoriatic arthritis (PsA) by both rheumatology and dermatology healthcare professionals.

Patients with Psoriatic Arthritis experience symptoms that involve both the skin and the joints, impacting their quality of life. Given the nature of the disease, patients may seek care from both dermatologists and rheumatologists, as the disease progresses through periods of flare and remission. A collaborative approach to treatment by a combined team of rheumatology and

dermatology clinicians allows for a unique blend of expertise and provides the opportunity for comprehensive care for the PsA patient.

It is expected that projects will be evidence-based and the proposed evaluation will follow generally accepted scientific principles. During review the intended outcome of the project is given careful consideration and, if appropriate based on the project goal, projects with the maximum likelihood to directly impact patient care will be given high priority.

It is NOT our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience: Rheumatology and Dermatology healthcare professionals caring for patients with or at risk for psoriatic arthritis.

Disease Burden Overview: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis in the setting of skin or nail psoriasis. The exact prevalence is unknown and has been difficult to estimate, however; researchers agree that PsA impacts 2-3% of the general population. PsA is a well-recognized cause of chronic joint damage, disability and poor Quality of Life (QoL). The condition is often undiagnosed and treatment algorithms are poorly defined.

Award Amount: $350,000
Indirect Costs: 28%
LOI Deadline: Jun 23, 2017
Website: http://www.pfizer.com/purpose/medical-grants/request-proposals

21. Research in Transforming Health & Health Care Systems, Robert Wood Johnson Foundation (RWJF)

The Foundation's new Research in Transforming Health and Health Care Systems (RTHS) call for proposals (CFP) seeks to fund rigorous, empirical studies that evaluate or predict the potential effects of policies or policy changes intended to transform health and health care systems. The 2017 RTHS CFP will focus on empirical and policy-relevant analyses that can inform strategies to ensure access to high-quality, affordable health care and insurance coverage. Projects may be generated from disciplines including health services research, economics, sociology, program evaluation, political science, public policy, public health, public administration, law, business administration, or other related fields.

Award Amount: $50,000-$150,000 for 6-12 months
Indirect Costs: 12%
Proposal Deadline: Jun 23, 2017
Website: http://www.rwjf.org/en/library/funding-opportunities/2017/research-in-transforming-health---health-care.html